Compare
Climb Bio, Inc. vs Corbus Pharmaceuticals Holdings, Inc. vs Gyre Therapeutics, Inc. vs Apimeds Pharmaceuticals US, Inc.
| Latest fiscal year | Climb Bio, Inc. CLYM | Corbus Pharmaceuticals Holdings, Inc. CRBP | Gyre Therapeutics, Inc. GYRE | Apimeds Pharmaceuticals US, Inc. APUS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $116.59M | n/a |
| Revenue growth (YoY) | n/a | n/a | +10.2% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | 9.9% | n/a |
| Net margin | n/a | n/a | 8.5% | n/a |
| Net income | -$59.85M | -$78.54M | $9.88M | -$6.00M |
| EPS (Diluted) | -$0.88 | -$5.90 | $0.02 | -$0.55 |
| Operating cash flow | -$54.36M | -$64.49M | $1.01M | -$8.93M |
| Free cash flow | -$54.54M | -$64.50M | -$180.0K | -$8.98M |
| Cash & equivalents | $35.69M | $28.49M | $37.07M | $1.64M |
| Total assets | $167.74M | $168.19M | $166.13M | $164.18M |
| Total liabilities | $7.27M | $20.69M | $23.85M | $10.84M |
| Shareholders' equity | $160.47M | $147.50M | $106.03M | $153.35M |
| Return on year-end equity | -37.3% | -53.2% | 9.3% | -3.9% |
| Shares outstanding | 47.77M | 17.61M | 91.31M | 12.58M |
Revenue, most recent five fiscal years
| Fiscal year | Climb Bio, Inc. | Corbus Pharmaceuticals Holdings, Inc. | Gyre Therapeutics, Inc. | Apimeds Pharmaceuticals US, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2022-12-31 | $116.59M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $881.7K Ended 2021-12-31 | $105.76M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $3.94M Ended 2020-12-31 | $113.45M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $36.14M Ended 2019-12-31 | $102.29M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $4.82M Ended 2018-12-31 | $7.34M Ended 2021-12-31 | n/a |